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ABSTRACT:
NECL-5 is involved in regulating cell–cell junctions, in cooperation with 
cadherins, integrins and platelet-derived growth factor receptor, that are essential 
for intercellular communication. Its role in malignant transformation was previously 
described. It has been reported that transformation of melanocytes is associated with 
altered expression of adhesion molecules suggesting the potential involment of NECL-
5 in melanoma development and prognosis. To shed light on this issue, the expression 
and the role of NECL-5 in melanoma tissues was investigated by bioinformatic and 
molecular approaches. NECL-5 was up-regulated both at the mRNA and the protein 
levels in WM35, M14 and A375 cell lines compared with normal melanocytes. A 
subsequent analysis in primary and metastatic melanoma specimens confirmed “in 
vitro” findings. NECL-5 overexpression was observed in 53 of 59 (89.8%) and 12 
of 12 (100%), primary melanoma and melanoma metastasis, respectively; while, 
low expression of NECL-5 was detected in 12 of 20 (60%) benign nevi. A significant 
correlation of NECL-5 overexpression was observed with most of known negative 
melanoma prognostic factors, including lymph-node involvement (P = 0.009) and 
thickness (P = 0.004). Intriguingly, by analyzing the large series of melanoma samples 
in the Xu dataset, we identified the transcription factor YY1 among genes positively 
correlated with NECL-5 (r = 0.5). The concordant computational and experimental 
data of the present study indicate that the extent of NECL-5 expression correlates 
with melanoma progression. 
INTRODUCTION
Cutaneous melanoma represents the most aggressive 
and lethal malignancy of the skin. Despite advances in 
melanoma treatment [1-4], mortality from melanoma 
is still increasing [5]. Melanoma prevention and early 
detection represent the best approaches to survive 
[6]. Discovery of biomarkers and their application, in 
conjunction with traditional cancer diagnosis, staging, and 
prognosis, could improve early diagnosis and patient care 
[7-9]. Thus, there is an urgent need to develop prognostic 
biomarkers that can differentiate between malignant 
and non-malignant skin lesions and identify melanoma 
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patients with high-risk primary lesions to facilitate greater 
surveillance. 
Many pathways were identified to play a role in 
melanoma development [10-11]. It is now well known that 
up- or downregulation of several adhesion molecules, such 
as N- and E-cadherin, MCAM (melanoma cell adhesion 
molecule), VCAM (vascular cell adhesion molecule), 
integrins, can be involved in the progression of several 
cancer types [12-16], including melanoma [17-19]. In 
this context, emphasis has recently been placed on the 
cell adhesion molecule, nectin like molecule-5 (NECL-
5), also named NECL-5/NECL-5/CD155/ Tage4 [20-23]. 
Experimental studies demonstrated that up-regulated 
NECL-5 enhances cell movement and proliferation and 
that cell-cell contacts do not induce a reduction of  NECL-
5 at the cell surface of NIH3T3 transformed cells (mouse 
embryonic fibroblast cell line) by oncogenic Ki-Ras; it was 
also suggested  that up-regulation of  NECL-5, mediated 
by activator protein-1 (AP1) pathway, might be involved 
in the loss of contact inhibition in transformed cells [24-
28]. Previous data showed that the down-regulation of 
NECL-5 in cancer cells decreases migration, proliferation 
and metastasis [25,29]. In the mean time, its upregulation 
has been observed in cancer cell lines [28-30], in human 
tumors such as glioblastoma, ovarian carcinoma, prostate, 
colorectal and lung cancer [31-35]. However, the 
involvement of NECL-5 in human cutaneous melanoma 
is still lacking. Overall, these data led us to investigate 
if NECL-5 expression may play a role in melanoma 
development and progression. 
In the present study, NECL-5 expression was 
observed at different levels in tissue samples from normal 
skin, benign melanocytic nevi and primary and metastatic 
melanoma suggesting that NECL-5 may be a potential 
marker of melanoma progression.
RESULTS
Computational analysis of  NECL-5 gene in 
melanoma datasets
Transcript levels were higher in primary and in 
metastatic melanoma samples when compared to those 
of normal samples by analyzing several public available 
melanoma datasets (Supplementary Figure 1).
NECL-5 is overexpressed in melanoma cell lines
We first analyzed the NECL-5 expression by western 
blot in WM35, M14 and A375 cell lines, compared with 
Figure 1: Expression analyses of NECL-5 in WM35, M14 and A375 cell lines. 1A) Western blot in WM35, M14 and A375 cell 
lines, compared with NHEM. The upper bands represent NECL-5 protein, and the lower bands are β-Actin used as an internal control. The 
intensities of these bands were quantified by the Kodak 1D image analysis software. 1B) mRNA expression of NECL-5 gene by RT-PCR 
using G6PD for normalization. 1C) Flow cytometry analysis of NECL-5 expression. Histograms compare staining with specific antibody 
(black line) with the appropriate isotype control antibody (gray line).
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NHEM.  NECL-5/β-Actin ratios were calculated for each 
of the three experiments and the average was used for the 
graph (Figure 1A). Although, western blots showed that 
NECL-5 is expressed in all of the cell lines, its expression 
in WM35 cells was significantly higher than that in 
NHEM cells (p< 0.001). In addition, analysis with one-
way ANOVA showed that NECL-5 protein levels were 
significantly higher in M14 and A375 cells compared to 
those in WM35 cells (p= 0.002). As expected, NECL-5 
mRNA levels were higher in M14 and A375 cells than in 
both WM35 and NHEM cells (Figure 1B). These results 
were also confirmed by flow cytometry analysis (Figure 
1C). Finally, IHC evaluation showed that NECL-5 protein 
is expressed in all melanoma cell lines (Supplementary 
Figure 2). In detail, NECL-5 immunolabelling was 
mainly localized at both extracellular and intracellular 
level of WM35, A375 and M14 cells and a stronger 
immunolabelling was observed in metastatic cell lines 
(Supplementary Table 2). 
siRNA of NECL-5 results in decreased melamoma 
cell migration
Knockdown of NECL-5 gene in both A375 and M14 
cells was used to understand the effect on cell migration. 
As shown in Figure 2, the transfection of NECL-5-specific 
siRNAs cause an almost 70% loss of NECL-5 transcript 
levels compared to control both in A375 and M14 cells. A 
reduction of 40% of invasive capacity was observed when 
NECL-5 was knocked-down in melanoma cells compared 
with control cells (p < 0.001). 
NECL-5 is overexpressed in melanoma tissues
IHC evaluation of NECL-5 was also performed in 
20 benign nevi and 71 melanoma specimens, including 
12 metastatic melanoma (Figure 3). Normal skin tissues 
showed no immunostaining (Figure 3a) whereas a positive 
immunostaining was in CMMs specimens (Figure 3c 
and 3d). The immunopositivity for NECL-5 was also 
significantly different between the benign (nevi) (Figure 
3b) and malignant lesions (primary and metastatic 
melanomas) (Figure 3c and 3d). Ten of 20 (50%)  benign 
nevi samples had minimal weak immunostaining of 
NECL-5. It was mainly detected in the outer zones of 
the rows of melanocytes and, almost absent, in cell-cell 
contacts between melanocytes (Figure 3b). In 3 nevi, 
NECL-5 immunostaining was present in the epidermis and 
upper dermis. Almost 91.5% of all melanoma specimens 
(primary and metastatic melanomas) showed an enhanced 
NECL-5 immunoreactivity (Figure 3c and 3d) when 
compared with the benign nevi tissue samples (Figure 
3b) (P<0.0001). In primary melanoma, NECL-5 staining 
was detected in cytoplasm and/or membrane of cancer 
cells. Immunoreactivity of NECL-5 was observed to be 
higher, within tumor cells, in metastatic melanomas than 
in primary melanoma (P<0.001). A  strongly labelled for 
NECL-5 there were in the papillary dermis, and variably 
in the reticular dermis and around blood vessels (Figure 
3d). As shown in Figure 3e and 3f, NECL-5 expression 
is higher in melanoma sections with thickness > 1 mm in 
comparison with those with thickness ≤ 1 mm.
The immunoreactivity was represented by the 
assignment of staining index (SI), in which the intensity of 
immunostaining was multiplied by the extent of positive 
area in the tissue samples. The mean ± SE of the staining 
index for benign nevi was 2.3 ± 0.51; while, it was 7.95 ± 
0.45 and 12.6 ± 1.58 for primary and metastatic melanoma 
samples, respectively (Suppl. Figure 3). In this analysis, 
primary and metastatic melanoma showed significantly 
higher level of NECL-5 expression than nevi (P<0.0001 
for both). As shown in the Table 2, 8 of 20 (40%) benign 
nevi were negative, only 2 of 20 (10%) displayed moderate 
and 10 of 20 (50%) had weak NECL-5 staining. We found 
that 51% of primary melanomas samples showed strong 
(30 of 59 cases) or 27% moderate (16 of 59) or 12% weak 
(7 of 59) immunostaining, whereas 6 of 59 (10%) were 
negative and those negative samples were all melanoma 
in situ. NECL-5 was immunohistochemically detected in 
all melanoma metastases. Of 12 metastasis, 8 of 12 (67%) 
showed strong staining, 3 of 12 (25%) moderate and 1 of 
12 (8%) had weak staining intensity. 
Figure 2: (A) siRNA of NECL-5 gene in both A375 and M14 cells  was used to understand the effect on cell migration. 
(B) siRNA of NECL-5 gene resulted in a significant decreased in transwell migration compared to control cells.  
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Correlation of NECL-5 expression with prognostic 
features in melanoma
We further examined a possible correlations between 
NECL-5 expression profiles in melanoma samples 
with their clinicopathologic features. Table 3 shows 
the potential association of NECL-5 expression levels, 
stratified according to the median NECL-5 immunoscore 
(< 9 and ≥ 9) with different clinicopathological features. 
As shown in Table 3, our analysis in melanoma tissue 
sections revealed that NECL-5 expression was strongly 
correlated with lympho node involvement (P = 0.009) and 
Table 1: Socio-demographic and clinical characteristics of patients with melanoma 
and benign nevi.
Cases of 
Melanoma Benign Nevi      χ2
n (%) n (%)
Sex
Male 42 (59) 14 (70)
Female 29 (41) 6 (30)   P=0.38
Age (years)
< 60 32 (45) 13 (65)
> 60 39 (55) 7 (35)     P=0.1
Type of cancer
Primary cutaneous melanoma 
including in situ melanoma 59 (83)
Metastatic melanoma 12 (17)
Type of primary melanoma
Superficial spreading 53 (74.6)
Nodular 18 (25.4)
Tumor localization
Head/neck                                                    2 (2.8) 1 (5)     
trunk                                                                 50 (70.4) 13 (65)     P=0.8
extremities 19 (26.8) 6 (30)
Breslow thickness
≤1 39 (54.9)
>1 32 (43.6)
Clark’s level
I/II 38 (53.5)
III 33 (46.5)
Ulceration of primary 
melanoma
Absent 55 (77.5)
Presente 16 (22.5)
Sentinel lymph node (SLN)
Negative 59 (83.3)
Positive 12 (16.7)
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Breslow thickness (P = 0.004). Lymph node spreading 
represents the most common way of metastasis in CMMs. 
As expected, the comparison between the group of 
melanoma sections with thickness > 1 mm and those with 
thickness ≤ 1 mm evidenced that NECL-5 immunoreactive 
scores were higher in thick (score: mean 10.53  ± 0.74, P = 
0.003) than in thin melanomas (score: mean 7.51 ± 0.59) 
(Supplemnetary Figure 4a). In particular, 81.2% (26 of 32) 
thick melanoma displayed 4 + of staining, 9.4% (3 of 32) 
had 3+ and 9.4% (3 of 32) showed 2+, while,  28.2% (11 
of 39) thin melanoma had 4+, 25.6% (10 of 39) had 3+ 
and 46.1% (18 of 39) showed 2+ of  NECL-5 staining. 
NECL-5 immunoscore was directly correlated with 
Breslow thickness (r = 0.59, P = 0.0001; Supplemnetary 
Figures 4b and 4c). These observations suggested a 
correlation between increased  NECL-5 expression and 
clinical progression in melanoma. However, no evident 
correlations were observed between  NECL-5 expression 
profiles and other clinicopathologic features, including 
age, sex, type of primary melanoma (superficial-spreading 
melanoma and nodular melanoma), Clark’s levels and 
ulcerations.
Positive correlation of NECL-5 with YY1 in 
melanoma 
To further confirm the association of NECL-5 with 
a more malignant phenotype in melanoma development, a 
positive correlation between NECL-5 and YY1 transcript 
levels has been identified by analyzing Oncomine software 
(r=0.468) (Figure 4a). In agreement with computational 
identification, immunohistochemistry evaluation 
reveals that both NECL-5 and YY1 were concomitantly 
overexpressed in melanoma samples (Figure 4b).
DISCUSSION
Cutaneous melanoma is the example of tumor type 
which progresses through various stages, from benign nevi 
to metastatic cancer, culminating in an highly aggressive 
disseminating tumor [40].
To our knowledge, this is the first report showing 
the expression of NECL-5 in primary and metastatic 
melanoma tissues and its correlation with some 
clinicopathologic features by using several independent 
approaches. These findings suggest its role in melanoma 
progression. A differential expression of  NECL-5 was 
detected between primary melanoma tissues and benign 
nevi. Only 60% of nevi displayed minimal or weak NECL-
5 expression, whereas 91.5% of melanoma specimens 
showed a high NECL-5 expression. The immunopositivity 
for NECL-5 protein was significantly different between 
the benign (nevi) and malignant (in situ, invasive and 
metastatic melanomas) lesions; whereas it was absent 
in normal skin. In benign nevi NECL-5 expression 
was mainly present in the outer zones of the rows of 
melanocytes and seemed to be almost absent in cell-
cell contacts between melanocytes, even if in three nevi 
NECL-5 immunostaining was present in the epidermis and 
upper dermis and declining with increasing depth. It might 
speculate that  NECL-5 expression in nevus cells enables 
them to invade into the dermis. Benign and atypical 
nevi have been shown to exist in clinical and histologic 
contiguity with cutaneous melanoma suggesting that 
these melanocytic nevi are also susceptible to malignant 
transformation [41]. These findings are consistent with 
other published reports describing the hypotetical role 
of  NECL-5 overexpression in different tumors [29,31-
35]. Most recently, Nakai et al. reported that  NECL-5 
expression is up-regulated in lung adenocarcinoma and 
has a negative effect on the prognosis of patients [35]. 
Previously, Ochiai et al. had shown that CD155 expression 
Figure 3: Immunostaining using a specific anti-
NECL-5 antibody in a representative fraction of 
human melanocytic lesions of benign nevi, primary 
and metastatic melanoma. Immunohistochemical analysis 
of NECL-5 in normal skin, benign nevi and melanoma tissues. 
a: Normal skin tissue shows no immunostaining for NECL-5 
(bar: 35 µm; inset, 15 µm).  b: Skin dermis of benign nevus 
tissue is weakly labelled for NECL-5 (bar: 32 µm). c: In primary 
melanoma lesion, immunolabelled melanocytes are immersed 
in a matrix also immunostained for NECL-5 (bar: 50 µm). d: 
Dermis and melanocytes of metastatic melanoma skin tissue are 
strongly labelled for NECL-5 molecule (bar: 50 µm). e: thickness 
≤ 1 mm; f: thickness > 1 mm;  NECL-5 expression is higher in 
melanoma sections with thickness > 1 mm in comparison with 
those with thickness ≤ 1 mm (bar: 50 µm).
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was up-regulated in several primary breast tumors [30]. 
Similarly, Sloan et al. observed that elevated espression of 
CD155 was detected in several primary cancer types [29]. 
In the current study, knockdown of the gene encoding 
NECL-5 in A375 and M14 cells caused a reduction of 
nearly 40% in tumor invasion capacity and provided 
further data that underline the role of  NECL-5 in the 
progression of malignant melanoma.
Our analysis in melanoma tissue speciments 
showed that the increase in NECL-5 immunoreactivity 
correlated with lymph node involvement and Breslow 
thickness that are considered to be major predictive 
factors in melanoma microstaging [45,46]. These results 
revealed that increased NECL-5 expression correlated 
with more aggressive behaviour. In fact, high NECL-5 
immunostaining in the nuclei and cytoplasm of cancer 
cells was detected in approximately more then 50% and 
83% of primary melanomas and metastatic samples, 
respectively. In agreement with our findings, previous 
study showed that transformed cells gain metastatic 
ability owing to upregulation of NECL-5 [26,28]. 
Many studies have demonstrated that overexpression 
of  NECL-5 is implicated in the loosening of contact 
inhibition and in the loss of epithelial integrity, so this 
enhances cell proliferation and migration may contribute 
to the dissemination of cells from tumors [28]. Other 
substrates of NECL-5 have been associated with 
cancer development and tumor progression. The loss 
of E-cadherin in melanocytic lesions would be found 
initially in nevi and more frequently in melanomas, this 
process appears to be one of the critical steps in the 
progression of melanoma [47]. The loss of E-cadherin in 
melanoma cells could trigger the release of cancer cells 
from the primary tumor by subsequent breakdown in 
the melanocytes–keratinocytes interaction and invasion 
of melanoma cells [47]. This suggests that increased 
expression of  NECL-5 may lead to elevated shedding 
of E-cadherin and loss of cell–cell contacts. E-cadherin-
mediated cell adhesion might be abrogated through 
degradation of the extracellular portion by gelatinases, as 
matrix metalloproteinases (MMPs)-2 [48]. Interestingly, 
it has been showed a novel link between  NECL-5 and 
MMP-2 expression in glioblastoma [49]. This study 
suggested that  NECL-5 enhance PI3K/Akt signalling at 
the leading edge during migration. The signaling guide 
to MMP-2 production, which can facilitate invasion. 
MMP-2 is strongly expressed in malignant melanomas 
and it correlates with invasion and metastatic behavior 
[50]. Thus, up-regulation of NECL-5 expression may be a 
common pathway through which cancer cells can acquire 
a more invasive or dispersive phenotype, a requirement for 
cancer progression [51]. 
Furthermore, the implication of NECL-5 with the 
aggressiveness of melanoma may be corroborate by its 
correlation with the transcription factor YY1. Our recent 
data showed that transcript levels of the transcription 
factor YY1 are higher in several cancer types including 
melanoma when compared with those of normal tissue 
[52-55]. We have also observed that the inhibition of YY1 
in A375 melanoma cells induces p53-mediated apoptosis 
after treatment with nitric-oxide donor [56]. These 
observations have lead us to investigate if YY1 transcript 
levels correlate with NECL-5 mRNA levels in melanoma. 
As aspected, by analyzing the large series of melanoma 
samples in the Xu dataset, we observed that YY1 is 
positively correlated with NECL-5 (r = 0.5) underlying 
that its overexpression is associated with a malignant 
phenotype in melanoma development.
In conclusion, we have provided evidence that 
NECL-5 may be an important biomarker in the early 
diagnosis of melanoma, being slightly expressed already in 
benign nevi. Moreover,  NECL-5 seems to be an indicator 
of tumour progression in melanoma. NECL-5 is strongly 
expressed in metastatic melanoma cell lines. In primary 
melanoma lesions was its expression was localized in 
the deeper part of the tumors and was consistent with 
a possible role in the progression toward an invasive 
phenotype. Limitations of our study is the absence of 
clinical follow-up, including survival data. Additional 
studies of the spectrum of expression of  NECL-5 and its 
relationship with other adhesion molecules and growth 
factors will be necessary to address further the complex 
processes of pathogenesis and progression in malignant 
melanoma. Our future goals will be to determine the 
molecular and cellular consequences as the result of an 
increased NECL-5 expression. These studies will allow 
the linking of  NECL-5 to specific signalling pathways 
so that rational mechanism-based therapeutic strategies 
directed at specific molecular targets can be developed 
toward the potentially better diagnosis and management 
Table 2: The staining intensity in melanocitic lesion 
Melanocytic  lesions Immunoscore
Strong Moderate Weak Negative
Benign nevi - 2/20  (10%) 10/20  (50%) 8/20 (40%)
Primary melanoma 30/59  (51%) 16/59  (27%) 7/59  (12%) 6/59 (10%)
Metastatic melanoma 8/12  (67%) 3/12  (25%) 1/12  (8%) -
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of melanoma.
MATERIALS AND METHODS
Gene expression data sets
Computational evaluation of NECL-5 has been 
performed by ONCOMINE software. Differential mRNA 
expression analyses among normal skin tissue versus 
benign melanocytic skin nevus (BMN), BMN versus 
cutaneous malignant melanoma (CMM) and CMM 
versus metastatic melanoma were explored in 3 datasets 
showing statistical significance less than 0.05 (p<0.05) 
[36-38]. Statistical analysis was accomplished through 
use of ONCOMINE algorithms. Haqq Melanoma Dataset 
was excluded from the study as a different microarray 
platform has been used by the authors [39]. Fold change 
values were considered for this analysis. Further details 
Figure 4: Correlation of YY1 with NECL-5 in melanoma. Heat map of genes positively correlated with NECL-5 (r = 0.5) by 
Pearson correlation analysis in the Xu melanoma dataset (A). Immunohistochemistry evaluation of NECL-5 and YY1 in a representative 
case of melanoma respectively in Panel (a) and (b) (B).
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on datasets are reported in Supplementary Table 1. 
Correlation between NECL-5 and Yin Yang 1 (YY1) 
transcript levels was analyzed according to Oncomine 
software in the Xu Melanoma Dataset [38].
Cell lines and culture conditions
Melanoma cell lines (WM35, A375, M14) and 
human epidermal melanocyte (NHEM) cell line were 
kindly provided by Dr.V. Russo (Tumor Targeting 
Research Unit, San Raffaele Scientific Institute, Milano, 
Italy) and Dr. R. De Maria (Department of Hematology, 
Oncology and Molecular Medicine, Istituto Superiore 
di Sanità, Rome, Italy), respectively. Melanocytes and 
melanoma cell lines were maintained in Melanocyte 
Growth Medium (Lonza, Walkersville, USA) and 
RPMI medium (Gibco, Life Technologies Inc., Milan, 
Italy), supplemented with 2 mmol/l L-glutamine, 100 
IU penicillin and 100 µg/ml streptomycin and 2% heat-
inactivated fetal calf serum (Gibco Life Technologies 
Inc.), respectively. All cell lines were cultured at 37°C in 
5% CO2 atmosphere at constant humidity and passaged 
twice a week. Melanocytes and melanoma cells were 
grown to subconfluency, harvested and subjected to westen 
blot, real-time polymerase chain reaction (RT-PCR) or 
flow cytometry and immunoistochemistry analysis (IHC).
Tissue samples and patients characteristics 
Archival paraffin tissue section of 91 melanocytic 
lesions excised between 2006 and 2010 were retrieved 
from the Department of Pathology at the Vittorio 
Emanuele Hospital, Catania, Italy. The collection and 
storage of samples were performed according to local 
ethical guidelines. Institutional review board approval 
was obtained for this study. There were (i) 59 CMM, 
including 10 melanoma in situ, (ii) 12 metastatic 
malignant melanoma, randomly chosen for the study, (8 
subcutaneous melanoma lesions and 4 regional lymph 
node metastases), (iii) 20 BMN, (iv) 10 normal skin 
adjacent to different tumour masses. Clinical staging of 
CMM was performed on a pathological basis according 
to the new American Joint Committee on Cancer 2001 
classification system. Diagnosis and staging of BMN had 
been performed on the basis of clinical, histopathologic 
findings. All sections of CMM were superficial spreading 
melanoma (SSM) and nodular melanoma (NM), at 
different stages (Clark’s level I to III). Localization of 
the primary melanoma were grouped in three classes: 
head/neck, trunk, extremities. We stratified CMM by 
the Breslow tumor thickness as thin (≤1mm) and thick 
(>1mm). Specimens were fixed in neutral 4% buffered 
formaldehyde for a minimum of 24h and subsequently 
embedded in paraffin. The clinicopathological features of 
91 melanocytic lesions are summarized in Table 1. 
RT-PCR analysis 
Total cellular RNA was extracted from cultured 
cell lines with Micro-to-Midi total RNA purification 
system (Invitrogen, Milano, Italy) according to the 
manufacture’s instructions. Reverse transcription 
was carried out using M-MLV reverse transcriptase 
(Invitrogen) and random primers (Invitrogen). 
Semiquantitive PCR was carried out by applying standard 
condition. The following primers were used (5’→3’): 
CD155 sense: TATCTGGCTCCGAGTGCTTGCC; 
CD155 antisense ACGACGGCTGCAAAAGTGGCG; 
glucose-6-phosphate dehydrogenase (G6PD) sense: 
ACGTGATGCAGAACCACCTACTG; G6PD antisense: 
ACGACGGCTGCAAAAGTGGCG. For quantitation, 
gels were scanned, and the pixel intensity for each band 
was determined using the Image J program and normalized 
to the amount of G6PD.
Immunoblot Analysis
Immunoblot analysis was performed as described 
by Merrill et al.[31]. Antibodies included anti-CD155 
(ab 103630, Abcam, Cambridge, UK) and anti-β Actin 
(Sigma-Aldrich). CD155 antibody binding was detected 
with streptavidin-horseradish peroxidase complex 
(Roche, Indianapolis, IN) and visualized using enhanced 
chemiluminescence substrate (Amersham Life Science, 
Piscataway, NJ, USA). β Actin was used as an internal 
loading control.
CD155 siRNA
A double stranded siRNA oligonucleotide targeting 
CD155 (5’-CAACUUUAAUCUGCAACGUdTdT-3’) 
was chemically synthesized (Dharmacon Research) 
and transfected into WM35, A375 and M14 cells using 
Oligofectamine (Invitrogen) following manufacturers 
instructions using 200 nM siRNA per 10 cm dish. Cells 
were incubated with siRNA in OptiMEM (Invitrogen) for 
6 hrs after which time normal growth media was added. 
Cells were then incubated for 72 h to achieve >80% 
knockdown of CD155. Control cells were transfected 
with a scrambled siRNA oligonucleotide at matching 
concentration. After transfection, cells were harvested and 
subjected to the invasion assay.
Tumor invasion assay
The in vitro invasion assay was done by using a cell 
invasion assay kit based on the manufacturer’s protocol 
(Chemicon, Billerica, MA). Control cells and siRNA-
treated cells were trypsinized and used for the invasion 
assay. 
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Immunohistochemistry
Immunohistochemical staining of NECL-5 were 
done according to standard protocols using CD155 
antibody (ab60115, Abcam, Cambridge, UK). Detection 
of primary antibody was performed using the streptavidin–
biotin–peroxidise complex system (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA)., according to the 
manufacturer’s instructions. The detection was carried out 
using Histostain-Plus Kit (Zymed, South San Francisco, 
CA). AEC (3-amino-9-ethylcarbozole) was used as a 
chromogen. Negative control experiments were performed 
as above described. Detection of YY1 was performed by 
using Sigma Aldrich HPA001119 antibody according to 
the manufacturer’s instructions.
Image analysis
Immunolabelled and sampled tumor sections were 
observed using a Leica DMRB microscope (10× and 40× 
magnification) (Leica, Wetzlar, Germany), the images were 
photographed with a Canon G-9 camera (Canon, Japan) 
and analyzed using Image J software. Four randomly 
chosen fields of view were assessed in the melanoma 
biopsies and in the cell lines. A section was considered 
negative or positive according to the absence or presence 
of cytoplasmic staining. Immunoreactivity was assessed 
by the amount of positive malignant cells in the area. We 
used a staining index (SI; values 0-16) with the following 
formula: SI = immunostaining intensity x positive area, 
where intensities were scored semiquantitatively as 
follows: 4+, very strong;  3+, strong; 2+, moderate; 1+, 
weak and 0, negative. Positive areas were defined as the 
epithelial area that showed positive malignant cells for 
NECL-5 immunoreactivity and was graded on an arbitrary 
scale as 0, absent; 1+, less than 25%; 2+, 25% to 50%; 3+, 
51% to 75%; and 4+, more than 75%. The distribution of 
staining was classified as focal or diffuse. Localization of 
staining (membranous or cytoplasmic) was also recorded. 
Scoring was based upon the consensus of three anatomic 
pathologists. 
Flow cytometry analysis
Cell lines were washed in PBS. Cell suspension 
were stained with phycoerythrin conjugated mouse IgG1 
isotype control and mouse IgG1 anti-CD155 (Bioscience, 
USA). Cells were analyzed using a FACScalibur flow 
cytometer (Becton Dickinson, USA). After gating cells on 
a forward scatter/side scatter dot plot window on linear 
scale, the fluorescence intensity of PE-conjugated isotype 
control and anti-CD155 labelled cells were analyzed in 
histograms on FL2 channel with logarithmic scales.
Statistical analysis
The statistical analyses were performed using SPSS 
for Windows. Comparison of socio-demographic and 
clinical characteristics benign nevi and melanoma patients 
was performed with the χ2 test. Normally distributed 
data were expressed as media ± SE and non normally 
distributed data were expressed as median (range). To 
correlate NECL-5 staining index and clinicopathologic 
features was applied the χ2 square test. Additionally, the 
correlations between  NECL-5 expression in melanoma 
sections and Breslow thickness were assessed by 
Spearman rank correlation. For semiquantitative RT-PCR 
analysis, statistics was performed by using the unpaired 
Student’s t test. The statistical differences of  NECL-
5 expression level between primary and metastatic 
melanoma samples were calculated by Student t test or 
one-way analysis of variance (ANOVA). Differences were 
considered to be statistically significant at a level of p < 
0.05.
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